Abcam, ab234561, Human PRAME ELISA Kit

Size: 1 x 96Tests
Human PRAME ELISA Kit is a single-wash 90-min Simplestep used to quantify Human PRAME with a sensitivity of 83 pg/ml. The assay uses a simple mix-wash-read protocol with just one incubation and one wash step. - Colorimetric Sandwich ELISA - 450 nm readout : works on any standard plate reader - Design your own immunoassay: we also offer the conjugation-ready antibody pair
Key facts
Detection method:Colorimetric,
Sample types:Cell culture extracts, Tissue Extracts,
Reacts with:Human,
Assay type:Sandwich (quantitative),
Sensitivity:= 83 pg/mL,
Range:0.313 - 20 ng/mL,
Assay time:1h 30m,
Assay Platform:Pre-coated microplate (12 x 8 well strips)

Product details:
Human PRAME ELISA Kit ab234561 is a rapid single-wash 90-min Sandwich ELISA to measure Human PRAME in cell culture extracts, tissue extracts. This SimpleStep sensitivity is 83 pg/mL.
How the assay works
Human PRAME SimpleStep ELISA
employs capture antibodies conjugated to an affinity tag that is recognized by the monoclonal antibody used to coat our SimpleStep ELISA
plates. This approach to sandwich ELISA allows the formation of the antibody-analyte sandwich complex in a single step, significantly reducing assay time. See the SimpleStep ELISA
protocol summary in the image section for further details.
Assay Specificity
Our SimpleStep ELISA
kits use recombinant monoclonal antibodies rigorously validated to ensure the highest level of consistency and reproducibility, improved sensitivity and specificity and ease of scalability and security of supply.
Please refer to our protocol booklet for more details.
Human PRAME ELISA Kit ab234561 protocol summary
1. Mix: add samples/standards to the wells together with the capture and detector antibody cocktail. Incubate 1 hr at room temperature
2. Wash
3. Add TMB development solution - incubate for 10 min
4. Add Stop solution
5. Read the results on a plate reader at 450 nm
Design your own immunoassay
We offer the antibody pair used in this kit in a BSA and Azide-free format, ready for conjugation:
- Anti-PRAME antibody [EPR20366-113] - BSA and Azide free (Capture)
ab245019
- Anti-PRAME antibody [EPR20366-80] - BSA and Azide free (Detector)
ab245019
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Properties and Storage Information:
Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
PRAME also known as Preferentially Expressed Antigen in Melanoma is a protein typically weighing around 50 kDa. It is found mostly in testis tissue but also appears in several types of tumors including melanoma and some leukemias. PRAME does not show significant expression in most normal tissues making it a potential target for cancer therapies. Immunohistochemistry (IHC) techniques such as PRAME IHC and PRAME staining often use monoclonal antibodies like mAb EPR20330 to detect PRAME protein presence in various samples.
Biological function summary
PRAME acts as a repressor of retinoic acid signaling a process important for cell differentiation and growth. It does not directly form part of a complex but interacts with components involved in retinoic acid pathways. By binding to retinoic acid receptor complexes PRAME prevents activation of genes involved in cell cycle arrest and apoptosis contributing to unchecked cellular proliferation seen in certain cancers.
Pathways
PRAME participates in the retinoic acid and various oncogenic signaling processes. It influences the retinoic acid pathway by interfering with the retinoic acid receptor (RAR) signaling. This interference with key proteins like RAR disrupts the normal regulatory processes that typically inhibit cancer progression. PRAME's modulation of these pathways highlights its role in promoting tumor growth and survival.
PRAME has significant relevance to cancer particularly melanoma. It is often used as a biomarker for melanoma identification due to its overexpression in such tumors. Additionally PRAME's connection to acute myeloid leukemia (AML) emerges from its ability to act similarly in diverse malignant cells. In these diseases the overexpression of PRAME interferes with normal differentiation processes and allows for sustained proliferation of malignant cells suggesting its potential role as a therapeutic target or diagnostic marker in oncology.